Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M959Revenue $M55.5Net Margin (%)-67.6Z-Score0.1
Enterprise Value $M837EPS $-0.3Operating Margin %-55.0F-Score5
P/E(ttm))0Cash Flow Per Share $-0.5Pre-tax Margin (%)-67.6Higher ROA y-yY
Price/Book42.910-y EBITDA Growth Rate %-22.6Quick Ratio7.1Cash flow > EarningsY
Price/Sales17.45-y EBITDA Growth Rate %-23.2Current Ratio7.1Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-22.2Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)-183.1Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M123ROI % (ttm)-167.3Gross Margin Increase y-yN

Gurus Latest Trades with OREX

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
OREXJohn Burbank 2013-12-31 Sold Out -0.15%$4.72 - $6.83
($5.61)
$ 7.6927%Sold Out0
OREXJohn Burbank 2012-09-30 Buy 0.2%$3.77 - $7.39
($5.32)
$ 7.6931%New holding750,000
OREXGeorge Soros 2012-06-30 Sold Out -0.03%$3.16 - $6.37
($3.76)
$ 7.6951%Sold Out0
OREXGeorge Soros 2012-03-31 Buy 0.03%$1.68 - $5.01
($3.11)
$ 7.6960%New holding500,000
OREXJean-Marie Eveillard 2010-09-30 Sold Out -0.01%$3.9 - $6.77
($4.98)
$ 7.6935%Sold Out0
OREXJean-Marie Eveillard 2009-12-31 Add0.01%$6.44 - $9.39
($7.57)
$ 7.692%Add 83.33%220,000
OREXJean-Marie Eveillard 2009-09-30 Buy 0.01%$5.2 - $10.34
($7.89)
$ 7.69-3%New holding120,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

OREX is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


OREX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Booth Mark DChief Commercial Officer 2015-02-26Sell50,000$5.6835.04view
Turner Heather DSVP, Gen. Counsel & Secretary 2014-12-02Sell22,643$627.83view
Turner Heather DSVP, Gen. Counsel & Secretary 2014-11-25Sell31,388$5.8331.56view
BOCK LOUIS CDirector 2014-11-18Buy1,325$5.5837.46view
BOCK LOUIS CDirector 2014-11-12Buy27,052$5.5737.7view
Turner Heather DVP, Gen. Counsel & Secretary 2014-09-22Sell300,000$4.4771.59view
NARACHI MICHAELPresident and CEO 2014-09-15Buy50,000$4.7860.46view
Hagan Joseph PSr. VP, Corporate Development 2014-09-15Buy5,000$4.6963.54view
Hagan Joseph PChief Business Officer 2013-07-31Sell12,000$7.8-1.67view
Hagan Joseph PChief Business Officer 2013-07-26Sell10,000$7.43.65view

Press Releases about OREX :

Quarterly/Annual Reports about OREX:

News about OREX:

Articles On GuruFocus.com
Orexigen Therapeutics' Bright Future Mar 03 2015 
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
Weekly CEO Sells Highlight: Orexigen Therapeutics Inc, Gas Natural Inc, The Middleby Corporation, an Jul 16 2012 
Weekly CEO Sells Highlight: Gas Natural Inc, Encore Bancshares Inc, Staples Inc, and Orexigen Therap Jul 08 2012 
Arena Facing Increased Pressure from Peers Apr 23 2012 
Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 
Vivus Could Rocket on Success of Qnexa Apr 13 2012 
Steve Cohen Bets On Orexigen Ahead of FDA Approval Feb 01 2011 
Orexigen Therapeutics Inc. Reports Operating Results (10-Q) Nov 04 2010 
Orexigen Therapeutics Inc. Reports Operating Results (10-Q) Aug 06 2010 

More From Other Websites
Cohen Milstein Sellers & Toll PLLC Announces the Investigation of Orexigen Therapeutics, Inc. Mar 27 2015
US pre-open: Futures point to another day in the red ahead of Yellen's speech Mar 27 2015
Ahead of the Bell: Orexigen shares rise Mar 27 2015
Ahead of the Bell: Orexigen shares rise Mar 27 2015
Oxford Industries, Orexigen And GameStop Lead Thursday's After-Hours Movers Mar 26 2015
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events Mar 26 2015
Orexigen gets approval to market weight loss drug in Europe Mar 26 2015
Orexigen gets approval to market weight loss drug in Europe Mar 26 2015
Orexigen's Mysimba™ Approved in Europe for the Treatment of Obesity Mar 26 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of OREXIGEN THERAPEUTICS, INC. of... Mar 25 2015
OREX Shareholder Alert: Investigation on Behalf of Orexigen Therapeutics, Inc. Investors Announced... Mar 25 2015
Deadline in Lawsuit for Investors in Orexigen Therapeutics, Inc. (NASDAQ:OREX) Shares Announced by... Mar 24 2015
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From... Mar 23 2015
OREXIGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds... Mar 20 2015
IMPORTANT ANNOUNCEMENT: Wolf Haldenstein Adler Freeman & Herz LLP Announces That a Federal... Mar 20 2015
Can Orexigen Win Where Obesity-Drug Rivals Failed? Mar 18 2015
Zacks Industry Outlook Highlights: Orexigen, MannKind, Amgen, Medivation and Express Scripts - Press... Mar 18 2015
INVESTOR ALERT: Investigation of Orexigen Therapeutics, Inc. Announced by Glancy Binkow & Goldberg... Mar 16 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of OREXIGEN THERAPEUTICS, INC. of... Mar 16 2015
Law Offices of Marc S. Henzel Announces Securities Class Action Periods Mar 16 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK